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P2RX7 is an ATP-gated ion channel, which can also exhibit an open state with a considerably wider permeation.
However, the functional significance of the movement of molecules through the large pore (LP) and the intracellular
signaling events involved are not known. Here, analyzing the consequences of P2RX7 activation in primary myoblasts
and myotubes from the Dmdmdx mouse model of Duchenne muscular dystrophy, we found ATP-induced P2RX7-
dependent autophagic flux, leading to CASP3-CASP7-independent cell death. P2RX7-evoked autophagy was triggered
by LP formation but not Ca2C influx or MAPK1-MAPK3 phosphorylation, 2 canonical P2RX7-evoked signals.
Phosphoproteomics, protein expression inference and signaling pathway prediction analysis of P2RX7 signaling
mediators pointed to HSPA2 and HSP90 proteins. Indeed, specific HSP90 inhibitors prevented LP formation, LC3-II
accumulation, and cell death in myoblasts and myotubes but not in macrophages. Pharmacological blockade or genetic
ablation of p2rx7 also proved protective against ATP-induced death of muscle cells, as did inhibition of autophagy with
3-MA. The functional significance of the P2RX7 LP is one of the great unknowns of purinergic signaling. Our data
demonstrate a novel outcome—autophagy—and show that molecules entering through the LP can be targeted to
phagophores. Moreover, we show that in muscles but not in macrophages, autophagy is needed for the formation of
this LP. Given that P2RX7-dependent LP and HSP90 are critically interacting in the ATP-evoked autophagic death of
dystrophic muscles, treatments targeting this axis could be of therapeutic benefit in this debilitating and incurable form
of muscular dystrophy.
Introduction
Duchenne muscular dystrophy is a severe and incurable inher-
ited muscle disorder. It is characterized by a debilitating muscle
wasting caused by altered mechanical stability of muscle cell
membranes and altered signaling combined with inflammatory
infiltrations (For a review see ref.1). The membrane instability
and signaling abnormalities are caused by the absence of DMD/
dystrophin, the protein product of the mutant DMD gene.
DMD orchestrates formation and function of the DMD-
associated protein complex (DAPC), which links the cytoskele-
ton with the extracellular matrix and also anchors various signal-
ing proteins. DAPC is lost from the dystrophic sarcolemma.
Inflammatory cell infiltrations in Duchenne muscular dystrophy
muscles are triggered by the danger-associated molecular patterns
released as a result of sarcolemmal damage. Extracellular ATP
(eATP) functions as one such endogenous danger signal operat-
ing through purinergic P2 receptors.2 Cytoplasmic ATP levels in
skeletal muscles exist at particularly high concentrations (5 to
10 mM).3 When released in the dystrophic tissue, eATP is less
© Christopher NJ Young, Anthony Sinadinos, Alexis Lefebvre, Philippe Chan, Stephen Arkle, David Vaudry, and Dariusz C Gorecki
*Correspondence to: Dariusz C Gorecki; Email: darek.gorecki@port.ac.uk
Submitted: 03/14/2014; Revised: 06/27/2014; Accepted: 11/06/2014
http://dx.doi.org/10.4161/15548627.2014.994402
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The
moral rights of the named author(s) have been asserted.
www.tandfonline.com 113Autophagy
Autophagy 11:1, 113--130; January 2015; Published with license by Taylor & Francis
BASIC RESEARCH PAPER
efficiently eliminated because one of the lost DAPC members,
SGCA (sarcoglycan, a [dystrophin-associated glycoprotein]), is
an ATP-hydrolase.4 Clearly, the environment of dystrophic
muscles favors overactivation of P2 purinoceptors and this can be
amplified by upregulated expression and function of P2RX7
(purinergic receptor P2X, ligand-gated ion channel, 7) directly in
dystrophic Dmdmdx mouse myoblasts and myofibers.5
P2RX7 is the predominant purinoceptor involved in eATP
danger signaling: It is fully activated by significantly higher eATP
concentrations than any other P2X receptor, at levels which nor-
mally exist in damaged tissue only. P2RX7 is an ATP-gated ion
channel, activation of which triggers Ca2C influx and MAPK1-
MAPK3 (mitogen-activated protein kinase 1/3) phosphorylation.
Additionally, in response to prolonged, high eATP stimulation,
P2RX7 can exhibit a further open state with a considerably wider
permeation to molecules of up to 900 Da that may be associated
with cell death by apoptosis or necrosis.6,7 P2RX7 activation has
recently been shown to induce autophagy in various cell
types.8-11 Moreover, the latest studies have revealed that whereas
chronic, high-level activation is cytotoxic to cells,12 the low-level
P2RX7 stimulation can provide metabolic advantages.13 Despite
their obvious functional implications, the exact permeation path-
ways through LPs, the physiological significance of the move-
ment of large molecules across the membranes as well as the
intracellular signaling cascades involved are not fully known and
may differ in various cell types.
While studied extensively in immune cells, the significance of
P2RX7 activation in skeletal muscles is largely unknown. At low
eATP concentrations P2RX7 activation appears to affect prolifera-
tion and differentiation of myoblasts14,15 while high eATP levels
have been shown to be toxic to these cells.14 Therefore, abnormali-
ties in P2RX7 purinergic signaling found in dystrophic myoblasts
and myotubes may have significant functional consequences.
Indeed, in the mouse model for deficiency of DYSF/LGMD2B
(dysferlin), the increased P2RX7 expression has been linked to the
NLRP3 (NLR family, pyrin domain containing 3) inflammasome
upregulation typical for the inflammatory response.16 We have
therefore set out to analyze the mechanism and effects of activa-
tion of P2RX7 in dystrophin-deficient myoblasts and myofibers.
We show here that activation of P2RX7 on dystrophic myoblasts
and myotubes resulted in the formation of LPs in cell membranes,
autophagic flux, and cell death but not in apoptosis.
Macroautophagy (referred to as autophagy) is a highly con-
served mechanism by which long-lived cellular constituents,
organelles, and debris are sequestered within autophagosomes
and targeted for lysosomal hydrolysis and subsequent reuse. This
may occur in adaptation to stress stimuli such as nutrient depri-
vation17 or as a housekeeping method of maintaining cellular
homeostasis.18 Autophagy plays an essential role in normal mus-
cle function, controlling muscle mass,19 adaptation to exercise,20
and regulation of glucose metabolism.21 Malfunctioning skeletal
muscle autophagy therefore has severe consequences and has
been implicated in various muscle diseases, including DMD (For
a review see refs.22,23).
The emerging roles for both autophagy and P2RX7 in muscle
lead us to examine the involvement of P2RX7 in the autophagic
pathway in diseased muscle. Here we demonstrate that, in
muscles, HSP90 (heat shock protein 90) and HSPA2/HSP70
(heat shock protein 2) link P2RX7 LP formation to autophagy
and that the canonical mechanisms of P2RX7 activation such as
Ca2C influx and MAPK1-MAPK3 phosphorylation are not
essential for these effects. This work represents a novel mecha-
nism of coordination of muscle cell homeostasis by extracellular
nucleotides and is also the first demonstration that the mecha-
nism of P2RX7-induced autophagy operates via heat shock pro-
teins. This previously unrecognized pathway, in which
autophagy stimulation through P2RX7 LP formation contributes
to muscle disease, integrates previous separate observations that
P2RX78 and HSP9024 mediate autophagy induction and that
manipulations of P2RX7,5 heat shock proteins,25 and autoph-
agy26 in dystrophic muscles can modulate the severity of this
debilitating and lethal disease.
Results
P2RX7 activation triggers lytic pore formation and cell
death in dystrophic myoblasts
In cells expressing P2RX7 such as macrophages and dendritic
cells, formation of LPs permeable to dyes such as ethidium bro-
mide (EtBr) and cell death via apoptosis or necrosis are well-
documented responses to prolonged stimulation with high con-
centrations of eATP.27 When cultured as primary cells without
serum and assayed under conditions favoring LP formation in
macrophages,28 myoblasts displayed dye uptake, membrane bleb-
bing, cell shrinkage, and death consistent with the classical
P2RX7 response usually found in macrophages (Fig. 1A and
Video S1). At 3 mM ATP, EtBr uptake over a 30-min time
course was significantly higher in dystrophic than wild-type (Wt)
myoblasts, with no significant increase in fluorescence observed
in Dmdmdx p2rx7¡/¡ double-mutant myoblasts, demonstrating
that this effect was P2RX7-dependent (Figs. 1A and B). Pretreat-
ment with 100 nM A438079 (specific P2RX7 antagonist) signifi-
cantly reduced EtBr uptake in dystrophic and Wt myoblasts
(Figs. 1A and C). Subsequently, eATP-evoked cell death was
evaluated using PrestoBlue cell viability assay and LDH release
membrane integrity assay: eATP-mediated cell death was signifi-
cantly enhanced in dystrophic vs Wt myoblasts and these effects
were attenuated through P2rx7 ablation in Dmdmdx p2rx7¡/¡
myoblasts or receptor antagonism using A804598 (Figs. 1D and
E). Interestingly, the mechanism of LP formation does differ
between myoblasts and macrophages, which may reflect differen-
ces in P2RX7 expression levels between these cell types (see
below), also explaining our previous inability to demonstrate
P2RX7-dependent LP formation in myoblasts.5
P2RX7-dependent LP formation and autophagy induction
are linked in dystrophic myoblasts
Phosphoproteomic analyses in dystrophic myoblasts indicated
autophagy as a potential functional consequence of P2RX7 stim-
ulation. To investigate whether the observed LP formation and
cell death following eATP application were associated with
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autophagy, primary Dmdmdx
myoblasts were exposed to
1 mM BzATP (a more selec-
tive P2RX7 agonist) for
25 min in the presence of
3 mM Lucifer Yellow (LY), an
anionic marker of P2RX7-
dependent LP formation. Sig-
nificant increases in LY uptake
observed in BzATP-treated
dystrophic myoblasts indi-
cated that both anionic and
cationic pore pathways29 are
active in dystrophic myoblasts
(Fig. 2A). Immunolocalization
of MAP1LC3/LC3 (microtu-
bule-associated protein 1 light
chain 3), which is recruited to
the membrane of phagophores
(reviewed in ref.30), revealed
that cells displaying LP perme-
ability had significantly
increased number, size, and
density of clusters containing
both LY and LC3 (Figs. 2A
and B), indicating a previously
unidentified link between LP
formation and autophagy
induction during the early
stages of P2RX7-induced
autophagy, prior to the initia-
tion of autophagic cell death.
P2RX7 activation induces
LC3-II formation
independently of MAPK1-
MAPK3 pathway activation
in dystrophic myoblasts
To further investigate this
autophagy response, primary
myoblasts from either wild-
type or Dmdmdx mouse muscle
were exposed to 3 mM ATP
for up to 60 min in physiolog-
ical extracellular solution (i.e.,
normal sodium, calcium, and
magnesium) and cell lysates
from different time points
were analyzed for LC3-II, a
sensitive marker of autophagy
induction.31,32 The time-course experiments showed that dystro-
phic myoblasts displayed significantly heightened sensitivity to
eATP-evoked LC3-II production compared to wild-type cells,
with induction occurring 10 to 30 min following stimulation
(Fig. 3A). The use of Dmdmdx p2rx7¡/¡ double-mutant myo-
blasts confirmed the LC3-II response to be P2RX7-dependent
with no LC3-II being triggered in these cells following exposure
to P2RX7 agonist BzATP (1 mM) (Fig. 3B). Moreover, preincu-
bation of dystrophic myoblasts with P2RX7 antagonist Brilliant
Blue G (BBG, 10 mM) prior to stimulation with BzATP
(1 mM) resulted in a significant reduction in LC3-II generation
(Fig. 3C, upper panels and Fig. 3D). LC3-II formation
Figure 1. P2RX7 activation induces LP formation and cell death in dystrophic myoblasts. (A) Examples of EtBr
fluorescence in wild-type (Wt) and dystrophic Dmdmdx myoblasts following 30 min exposure to 3 mM eATP in LP
buffer (left panels). Right panels show EtBr uptake following the same treatment in myoblasts isolated from
Dmdmdx p2rx7¡/¡ double-mutant mice and Dmdmdx myoblasts after inhibition of P2RX7 by 30 min preincubation
with 100 mM A438079. Inset in Dmdmdx panel shows classic ‘macrophage-like’ membrane blebbing following
exposure of Dmdmdx myoblasts to eATP. (B) Summary data showing EtBr uptake dependence on P2RX7 expres-
sion in Wt, Dmdmdx and Dmdmdx p2rx7¡/¡ myoblasts exposed to 3 mM eATP for 30 min (C). eATP dose response
of EtBr uptake in Wt and Dmdmdx myoblasts exposed to indicated concentrations of ATP for 30 min, with or with-
out preincubation with 100 mM A438079. Digitonin represents permeabilized positive control. (D) PrestoBlue
fluorescence (cell viability) in Wt, Dmdmdx, and Dmdmdx p2rx7¡/¡ myoblasts following 30 min exposure to 3 mM
eATP. (E) LDH release from Wt, Dmdmdx, and Dmdmdx p2rx7¡/¡ myoblasts following 30 min exposure to 3 mM
eATP with or without the P2RX7-specific inhibitor, A804598 (100 nM). Mean C/¡ SE, n D 5, P < 0 .05* and
0.0001***.
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coincided with the latter half of the biphasic phospho-MAPK1-
MAPK3 response we previously described in Dmdmdx myoblasts
following P2RX7 activation.5 The MAPK1-MAPK3 activation
pathway is a positive regulator of autophagy induction.33 To
investigate whether the P2RX7-dependent LC3-II response
occurred via this signaling mechanism, cells were preincubated
with 100 mM of U0126 (MAP2K1/2 inhibitor), prior to agonist
application. The observed extent of reduction in LC3-II levels
indicated that MAPK1-MAPK3 signaling could not be identified
as the main pathway of autophagy activation in Dmdmdx muscle
cells (Fig. 3C lower panels and Fig. 3D).
No noticeable mitophagy was observed under these condi-
tions, as assessed using the COX4I1 (cytochrome c oxidase sub-
unit IV isoform 1) marker34 (Fig. 3A). However, mitochondria
shrank and retracted to a perinuclear localization following
30 min application of eATP (Fig. S1C), which coincided with
an increase in reactive oxygen species production (Figs. S1A and
B) and loss of mitochondrial membrane potential (see below).
This was in agreement with our previous observations that DMD
gene mutations affect energy metabolism in myoblasts.35
P2RX7-mediated LC3-II induction occurs via increased
autophagic flux in dystrophic myoblasts
The induction of autophagy is a self-regulating process seeking
equilibrium. Levels of LC3-II and therefore autophagosomes may
decrease through lysosomal fusion at the same time as they are
increased through stimulus, hence the turnover rather than simply
the endogenous level of LC3-II is seen as a marker for autophagy
induction.36 The term autophagic flux is used to define the crite-
ria for which a true increase in autophagy may be separated from
a cessation of lysosomal activity or autophagosome-lysosome
fusion.37 Flux may be distinguished from accumulation using
autophagy inhibitors and lysosomal protease inhibitors, where an
increase in autophagic flux should be accompanied by an addi-
tional increase in LC3-II accumulation in the presence of lyso-
somal protease inhibitors.32,38 In Dmdmdx myoblasts, the
combination of lysosomal protease inhibitors, pepstatin A (PepA)
and E-64d (both at 10 mg/ml) in conjunction with 1 mM BzATP
stimulation produced significant increases in LC3-II accumulation
when compared to 1 mM BzATP alone (Fig. 4A, upper panel
and Fig. 4B). Substituting PepA/E-64d with 1 mM mefloquine
hydrochloride (Mefloq., another agent that blocks lysosomal pro-
teases) also resulted in an increase in LC3-II accumulation in
myoblasts (Fig. 4A, lower panels and Fig. 4B). Preincubation
with 5 mM 3-MA (autophagy inhibitor) abolished BzATP-
evoked LC3-II production. As 3-MA is a class III phosphatidyli-
nositol 3-kinase (PtdIns3K) inhibitor, this result indicates that
P2RX7-mediated increases in autophagic flux in dystrophic myo-
blasts may occur via PtdIns3K-mediated pathways.
To investigate the potential involvement of the recently
described autophagic cell death pathway called autosis,39 digoxin
and digitoxigenin (both 10 mM) were used. These compounds,
at the concentration that specifically inhibits autosis, had no
effect on eATP evoked autophagic flux, LP formation, or cell
death (Figs. S2A and B). This lack of response to inhibitors cor-
responded with our other data showing features opposite of what
Figure 2. P2RX7-dependent LP formation is linked to autophagy induction in Dmdmdx myoblasts. (A) Representative images showing P2RX7-dependent
increases in Lucifer Yellow uptake (LY, green) and autophagy induction (LC3 aggregation, red) in Dmdmdx myoblasts exposed to 1 mM BzATP. LY uptake
was observed in cells displaying high levels of autophagy, where dye colocalized with LC3 immunofluorescence in distinct clusters. (B) ImageJ quantifica-
tion of LC3 clusters number, size, and density in LY-positive and LY-negative cells using 3D compilations of z-stacked confocal images, with an example
image shown. MeanC/- SE, n D 10, P D 0.0001***.
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was found in autosis. Specifi-
cally, P2RX7 activation caused
autophagic flux and cell detach-
ment observed within minutes
following stimulus, while in
autosis, cells showed no changes
until several hours poststimula-
tion at which stage they died
displaying increased substrate
adherence.39
We further investigated the
ability of P2RX7 to invoke
eATP-induced autophagic flux
by comparing LC3-II flux in
HEK-293 with that of HEK-
293 cells stably transfected with
mouse P2RX7 cDNA. Here
also, application of 1 mM
BzATP resulted in significant
increases in LC3-II in trans-
fected compared with control
HEK-293 cells and this effect
was again blocked and aug-
mented by the autophagy inhibi-
tor 3-MA and protease
inhibitors PepA and E-64d,
respectively (Figs. 4C and D).
To our knowledge, these repre-
sent the first demonstrations that
the P2RX7 can act as a positive
regulator of autophagic flux.
Phosphoproteomic analysis
of the early purinoceptor
signaling response in
dystrophic myoblasts
Putative P2RX7-evoked sig-
naling cascades in dystrophic
muscle cells were investigated
using an iTraq-based mass spec-
trometry approach. Phospho-
proteins extracted from wild-
type and dystrophic myoblasts
treated with 3 mM ATP for
10 min were analyzed using
Spectrum Mill (Agilent) and
inference values determined via
the iQuantitator algorithm.40
One thousand two hundred and
seventy two unique phosphopro-
teins were identified, of which
263 showed significant differen-
ces in their phosphorylation sta-
tus evoked by eATP. Pathway
analysis was performed using
MetaCore and IPA softwares.
Figure 3. eATP induces P2RX7-dependent autophagy in myoblasts. (A) Representative western blots showing
increased P2RX7 expression levels in dystrophic (Dmdmdx) vs. wild-type (Wt) myoblasts, with a time-course of
MAPK1-MAPK3 phosphorylation and autophagy induction (LC3-I to LC3-II shift) following exposure to 3 mM
eATP. No detectable changes in mitophagy were observed as shown by COX4 expression levels. ACTB repre-
sents protein loading control. (B) Western blots of triplicate samples showing the dependency of autophagy
induction on P2RX7 expression in myoblasts; note the lack of 17 to 14 kDa LC3 shift in Dmdmdx p2rx7¡/- double-
mutant myoblasts following 30 min exposure to 1 mM BzATP. (C) Western blots of triplicate samples showing
different effects of inhibiting P2RX7 activation and MAPK1-MAPK3 phosphorylation on autophagy induction in
Wt (left panel) and Dmdmdx (right panel) myoblasts. Cells were preincubated for 30 min with the P2RX7 antago-
nist Coomassie brilliant blue-G (BBG) or U0126 (MEK inhibitor) prior to 30 min 1 mM BzATP treatment. The clas-
sical P2RX7-MAPK1-MAPK3 activation cascade is involved in, but does not appear to be the sole pathway of
autophagy induction in dystrophic myoblasts. Note: The phospho-MAPK1-MAPK3 is a multichannel (green/red)
fluorescent blot, where yellow signal denotes increased MAPK1-MAPK3 phosphorylation. The left-hand lane in
the Wt blot is a positive control. (D) Fold change in LC3-II levels in response to treatments shown in (C). Mean
C/- SE, n D3, P < 0 .05* and 0.0001***.
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This approach identified significantly higher phosphorylation sta-
tus in HSPA2, HSPA8 (heat shock protein 8), 3 HSP90 isoforms
and in CDC37 (cell division cycle 37) members of the family of
chaperone heat shock proteins in dystrophic myoblasts. HSPA2
and HSP90 involvement in autophagy has also been docu-
mented24,41 and, moreover, P2RX7 functionally interacts with
these heat shock proteins as part of the P2RX7 signaling com-
plex.42 Therefore, having found heat shock proteins as potential
downstream orchestrators of P2RX7 signaling in dystrophic vs
wild-type myoblasts exposed to eATP (Figs. 5A and B) we investi-
gated whether heat shock proteins mediate the observed P2RX7-
dependent LC3-II response seen in dystrophic myoblasts.
P2RX7-dependent LC3-II flux in dystrophic myoblasts
requires large-pore formation and heat shock proteins but not
calcium channel activity
Dystrophic muscle cells cultured in the presence of HSP90
inhibitors (75 nM geldanamycin [GA] or 75 mM 17-DMAG)
or HSPA2 inhibitors (100 mM KNK437 or 100 nM
VER155008) showed no LC3-II formation following P2RX7
stimulation with 1 mM BzATP (Fig. 6A). This response was
independent of calcium influx as it was not blocked by 10 mM
BAPTA-AM (Fig. 6A). In contrast, A438079 (antagonist of the
P2RX7 LP formation)43 completely inhibited BzATP-induced
LC3-II flux (Fig. 6B).
Figure 4. P2RX7 activation induces autophagic flux in dystrophic myoblasts. (A) Representative protein gel blots of triplicate samples showing LC3-II
responses in dystrophic (Dmdmdx) and wild-type (Wt) myoblasts. LC3-II formation invoked following 30 min treatment with 1 mM BzATP was blocked by
the autophagy inhibitor 3-methyladenine (3-MA), while lysosomal protease inhibitors E-64d/pepstatin A and mefloquine (Mefloq.), which prevent the
degradation of autophagosomes, further enhanced LC3-II accumulation following BzATP treatment. (B) Fold changes of LC3-II conversion as a marker of
autophagosome formation. A significant compound increase in LC3-II was observed in cells treated with 1 mM BzATPC E-64d/pepstatin A or mefloquine
indicating that specific P2RX7 activation induces the formation of autophagosomes rather than blocks their degradation. Significant decreases in LC3-II
observed in cells pretreated with 3-MA may indicate that P2RX7-dependent autophagosome formation occurs via a PtdIns3K-dependent mechanism.
(C) P2RX7 expression confers eATP-dependent autophagic flux response to HEK-293 cells. Note no LC3-II response in untransfected (HEK-293-P2RX7 neg-
ative, upper panel) and very significant activation in P2RX7-transfected cells (HEK-293-P2RX7 expressing, lower panel) following 30 min treatment with
1 mM BzATP. This effect was blocked by autophagy inhibitor 3-MA (5 mM) and increased by lysosomal protease inhibitors PepA and E-64d (both at
10 mg/ml). (D) Fold changes of LC3-II responses observed in BzATP-treated HEK cells from (C). Mean C/- SE, n D 3, P < 0 .05*, 0.001** and 0.0001***.
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Figure 5. For figure legend, see page 120.
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HSP90 has previously been shown to functionally interact
with BECN1/Beclin 1 in macrophages, where GA treatment
inhibits LC3-II responses through degradation of BECN1.24
Therefore, we investigated the effect of the HSP inhibitors GA
and KNK437 on BECN1 expression in dystrophic myoblasts.
Contrary to findings in macrophages, where inhibition of
HSP90 but not HSPA2 reduced BECN1 expression,24 dystro-
phic myoblasts showed dose-dependent increases in BECN1 lev-
els following HSP90 or HSPA2 inhibition, with EC50 12.72 nM
for GA (Fig. 6C).
This was unexpected as increases in BECN1 are normally
associated with increased autophagy. Therefore, we performed an
aggresome assay in cells treated with BzATP and GA to test
whether, in the absence of the chaperone activity of HSP90,
BECN1 might form aggregates. Indeed, clear colocalization of
BECN1 with aggresomes was observed in cells pretreated with
GA (Fig. 6D), indicating that HSP90 inhibition in dystrophic
myoblasts causes targeting to and accumulation of nonfunctional
BECN1 in aggresomes.
P2RX7 LP formation in myoblasts is autophagy-dependent,
HSP90-dependent, HSPA2-independent and a trigger for
autophagy in myoblasts but apoptosis in macrophages
Preincubation with 5 mM 3-MA for 1 h prior to 30 min
3 mM ATP application blocked all EtBr uptake in myoblasts
(Figs. 7A and B) and also significantly reduced LDH release (not
shown). The HSP90 inhibitor GA, but not the HSPA2 inhibitor
KNK437, prevented P2RX7 LP formation in myoblasts. In con-
trast, these effects were not observed in macrophages, indicating
cell-specific responses (Figs. 7A and B).
P2RX7 stimulation in macrophages induces loss of mitochon-
drial membrane potential and CASP3-CASP7 (caspase 3-caspase
7)-dependent cell death.44 Therefore, we have examined whether,
in myoblasts, the same process can coexist with autophagy. Time-
lapse live cell images were collected during continuous incuba-
tions in tetramethylrhodamine ethyl ester perchlorate (TMRE,
200 nM) to monitor mitochondrial membrane potential and
DEVD-NucView488 (5 mM) to monitor CASP3-CASP7 activ-
ity. Exposure to 3 mM eATP caused loss of mitochondrial mem-
brane potential noticeable within 1 or 2 min in both
macrophages and myoblasts. Thereafter, during the period of 10
to 30 min >80 % of macrophages displayed progressively
increasing CASP3-CASP7 activity (Fig. 7C), exactly as previ-
ously described.44 In contrast, this CASP3-CASP7 response was
not observed in either wild-type or dystrophic myoblasts
(Fig. 7C). No signal was observed in myoblasts even after 2 h
incubation with eATP (data not shown). One mM staurosporine
was sufficient to induce CASP3-CASP7 activation in >90 % of
wild-type and dystrophic myoblasts within 2 h of addition
(Fig. 7C), confirming these cells capacity to undergo canonical
apoptosis and indicating differences in P2RX7-induced cell death
cascades between myoblasts and macrophages.
Dystrophic myotubes also respond to eATP with P2RX7-
dependent LP formation, LC3-II induction, and cell death
Myoblasts, as the proliferating precursors of muscle cells, dif-
fer significantly in their biology and pathology from differenti-
ated, multinucleated, contractile muscle-forming myotubes.
Therefore, we sought to establish whether the effects of P2RX7
activation found in dystrophic myoblasts, are indeed retained by
myotubes. Exposure to 3 mM eATP for 30 min induced signifi-
cant EtBr fluorescence in wild-type and dystrophic myotubes,
with dystrophic cells displaying increased responses (Figs. 8A
and B). The Dmdmdx p2rx7¡/¡ myotubes did not show LP for-
mation following eATP stimulation (Fig. 8A, lower panels and
Fig. 8B, left panel), confirming eATP responses as P2RX7-spe-
cific. Significant reductions in EtBr fluorescence were observed
when dystrophic myotube cultures were preincubated with
5 mM 3-MA (autophagy inhibitor), 75 nM GA (HSP90 inhibi-
tor) (Figs. 8A and B) or 100 mM A438079 (Fig. 8B). P2rx7
ablation also significantly reduced LDH release from myotubes
following eATP treatment (Fig. 8C, left panel), as did preincuba-
tion with 3-MA and A804598 (P2RX7 antagonist) (Fig. 8C,
right panel). Moreover, dystrophic myotubes displayed signifi-
cantly increased BzATP-evoked LC3-II generation compared to
wild-type cells, a response not seen in Dmdmdx p2rx7¡/¡ myo-
tubes (Fig. 8D).
Discussion
Several studies, including our own, have previously shown
increased P2RX7 expression and activity in dystrophic muscles of
the Dmdmdx mouse model of DMD.5,15,45 Here we document
the functional significance of P2RX7 activation in muscle cells,
which while having some resemblance to the canonical macro-
phage response, showed a very significant difference in cell death
pathways. In contrast to macrophages, eATP triggered oxidative
stress but no mitophagy nor apoptosis in myoblasts. Specifically,
the absence of eATP-induced CASP3-CASP7 activation44 in
myoblasts and the lack of protection from eATP by autophagy
inhibitors in macrophages, are the most striking. In mouse
microglia8 and in human retinal pigmented epithelial cells,46
P2RX7 signaling has been reported to negatively regulate
Figure 5 (See previous page). Phosphoproteomic analysis of ATP treated dystrophic vs. normal myoblasts. (A) Sample of analysis report generated using
iQuantitator40 showing fold increases in phosphoproteins detected in dystrophic vs normal myoblasts stimulated with 3 mM ATP for 10 min. Numbers of
peptides and sequences detected are shown with percentage sequence coverage per protein. (B) IPA Path Designer software (Ingenuity) analysis of sig-
naling cascade activation following 10 min 3 mM ATP treatment of dystrophic myoblasts. Molecules are represented as nodes relating to known func-
tional class of molecule (see key); relationships between molecules (supported by at least one literature citation) are depicted as lines. The intensity of
the molecular color denotes degree of up- (red) or downregulation (green). Heat shock proteins have been artificially highlighted here to aid interpreta-
tion of the illustration. Large oval outlines denote general clustered changes in phosphorylation status of related molecules: 1 D down regulation of
translation, 2 D upregulation of proteasome, 3 D upregulation of tubulin rearrangements.
120 Volume 11 Issue 1Autophagy
autophagic flux through the
impairment of lysosomal func-
tions. Yet increases in flux have
been reported in monocytes and their derived macrophages fol-
lowing P2RX7 activation during mycobacterial infection,9 thus
supporting our data and emphasizing cell-specific and functional
differences in the way in which purinergic receptors can affect
autophagy.
P2RX7 is an ATP-gated ion channel, activation of which trig-
gers Ca2C influx and MAPK1-MAPK3 phosphorylation but this
receptor can exhibit a further open state with a considerably
wider permeation,7 allowing uptake of dyes such as EtBr and LY
used in this study. Our data agrees with previous observations
that LP formation can vary in different cells and we also
confirmed that assay conditions play an important role.47 Cru-
cially, using specific antagonists we have shown that it is the LP
formation that triggers autophagy in muscle cells. Moreover, LY
entering through the LP was targeted to LC3-positive organelles,
presumably autophagosomes. It is tempting to speculate that the
same may apply to specific biomolecules. However, no physio-
logically-relevant compounds, which enter cells via the LP, have
been identified so far. In addition, there was a reciprocal effect
where LP formation in myoblasts but not macrophages was
blocked by the autophagy inhibitor 3-MA. These differences
may be related to the significantly lower levels of receptor
Figure 6. Heat shock proteins and
LP formation mediate P2RX7-
dependent LC3-II shift indepen-
dently of calcium influx in dystro-
phic myoblasts. (A and B)
Representative immunoblots of
LC3-II and BECN1 levels in dystro-
phic myoblasts stimulated with
1 mM BzATP following preincuba-
tion with 2 sets of HSP90 and
HSPA2 inhibitors, KNK437 and gel-
danamycin (A) and 17-DMAG and
VER155008 (B). Graphs in (A) and
(B) denote fold changes in LC3-II
and BECN1 expression shown in
adjacent blots (T/C D Treated/Con-
trol). P2RX7 channel activity and LP
formation effects were assessed
using BAPTA-AM (A) and A438079
(P2RX7 pore-specific antagonist, B),
respectively. (C) Inhibition of HSP90
or HSP 70 caused a dose-depen-
dent increase in BECN1 expression
in dystrophic myoblasts. The
Dmdmdx myoblasts were treated
with indicated concentrations of
GA or KNK437 for 16 h (left panel),
or with 75 nM GA for indicated
time periods (right panel) and then
lysed. Nonlinear curve fitting func-
tion of GRAPHPAD Prism V6.01 was
used to determine EC50 of
12.72 nM for GA. (D) Inhibition of
HSP90 results in targeting of BECN1
to aggresomes in dystrophic myo-
blasts. The Dmdmdx myoblasts were
stimulated with 1 mM BzATP with
or without pretreatment with
75 nM GA, as indicated. Control
cells showed puncta of BECN1
staining (green signal) separate
from the Proteostat aggresome
marker (red) while in cells pre-
treated with GA there was colocali-
zation of BECN1 with aggresomes
(yellow signal). Mean C/¡ SE, n D
3, P < 0 .05* and 0.001**.
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expression in dystrophic myoblasts, which are <25 % of that
found in the macrophage cell line J774 or the stably transfected
HEK cells (Figs. S3A and B). However, a muscle-specific signal-
ing mechanism should also be considered.
We investigated the mechanism
involved in this previously unrecog-
nized link between P2RX7 pore for-
mation and autophagy using
combinations of specific agonists and
antagonists. First, we found that the
autophagic response in dystrophic
myoblasts does not require the extra-
cellular Ca2C influx associated with
the ion channel function of the
P2RX7. Furthermore, while the
MAPK1-MAPK3 activation pathway
plays some role, as shown by the par-
tial inhibition of autophagic flux with
U0126, this was not the most signifi-
cant signaling pathway in autophagy
triggered by P2RX7 stimulation. A
recent study in tumor cells has identi-
fied a novel signaling axis following
activation of P2RX7 that involved
PRKA/Protein kinase, AMP-activated,
AKT1S1/AKT1 substrate 1, and
MTOR/mechanistic target of rapamy-
cin.11 Given the data showing autophagy stimulation via
AMPK agonist and MTOR blocker administration to amelio-
rate Dmdmdx pathology,48 the existence of such a pathway in
muscles should be investigated.
Figure 7. Mechanisms of eATP-induced LP
formation and cell death differ between
myoblasts and macrophages (MØs). (A)
Images of EtBr fluorescence in Wt and
Dmdmdx myoblasts and Wt MØs following
30 min exposure to 3 mM eATP with or
without preincubation with the autophagy
inhibitor 3-methyladenine (3-MA, 5 mM),
the HSP90 inhibitor GA (75 nM) or the
HSPA2 inhibitor KNK437 (100 nM). (B) EtBr
uptake in Wt and Dmdmdx myoblasts fol-
lowing 30 min exposure to 3 mM eATP
with and without 30 min preincubation
with autophagy inhibitors 5 mM 3-MA, or
0.2 mM wortmannin (left panel), or follow-
ing preincubation with HSPA2 inhibitors,
KNK437 and VER155008, HSP90 inhibitors,
geldanamycin (GA) and 17-DMAG, or the
P2RX7 LP-specific antagonist A438079.
Mean C/- SE, n D 3, P < 0 .05* and 0.001**.
(C) Time-lapse live cell confocal micros-
copy-based visualization of mitochondrial
membrane potential (red) and CASP3-
CASP7 activity (green) in wild-type (Wt)
and dystrophic (Dmdmdx) myoblasts and
wild-type macrophages (MØs) exposed to
3 mM ATP for the indicated time. One mM
Staurosporine treatment represents posi-
tive control for apoptosis. eATP induced
cumulative increases in CASP3-CASP7
activity in MØs but not in myoblasts.
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However, we focused our atten-
tion on a novel pathway discov-
ered in proteomic analyses used
to identify downstream orches-
trators of P2RX7 signaling in
dystrophic myoblasts. Proteo-
mics pointed toward chaperone
heat shock proteins and indeed, pharmacological inhibitors of
HSPA2 and HSP90 blocked LC3-II formation in myoblasts
exposed to eATP. When heterologously expressed in HEK cells,
P2RX7 has been shown to physically interact with a large
complex of proteins, including HSPA2 and HSP9042 and these
proteins are known to associate with each other via a protein
called STIP1.49 HSP90 associated with the P2RX7 complex is
tyrosine-phosphorylated and decreasing tyrosine phosphorylation
using geldanamycin produced increased sensitivity of P2RX7 to
agonist and membrane blebbing, thus suggesting a nonchaperone
function of HSP90 as a negative regulator of P2RX7.50 Here we
confirmed that this is a physiological interaction that also occurs
in primary myoblasts and myotubes. Moreover, in muscle cells
this interaction is associated with a novel downstream event in
the plethora of pathways triggered by this receptor, namely
Figure 8. eATP induces
P2RX7-mediated LP formation
and autophagy in dystrophic
myotubes. (A) EtBr fluores-
cence in Wt, Dmdmdx, and
Dmdmdx p2rx7¡/¡ myotubes
following 30 min exposure to
3 mM eATP with and without
preincubation with the
autophagy inhibitor 3-MA
(5 mM) or with the HSP90
inhibitor geldanamycin (GA,
75 nM). Note the absence of
response in Dmdmdx p2rx7¡/¡
myotubes lacking P2RX7. Digi-
tonin (50 mg/ml) represents
permeabilized positive con-
trols. (B) Summary data
representing EtBr uptake in
Wt and Dmdmdx myotubes
shown in (A). eATP-dependent
increases in EtBr fluorescence
were observed in both Wt and
Dmdmdx myotubes with
Dmdmdx displaying signifi-
cantly higher uptake relative
to Wt cells. In both Wt and
Dmdmdx myotubes, preincuba-
tion with P2RX7 antagonist
A438079 (100 mM), 3-MA
(5 mM) or GA (75 nM) pro-
duced significant reductions
in eATP-induced EtBr fluores-
cence. Three-MA alone
blocked EtBr background sig-
nal in unstimulated cells. (C)
Summary data of differences
in LDH release from Wt,
Dmdmdx and Dmdmdx p2rx7¡/¡
myoblasts following 30 min
exposure to 3 mM eATP, and
Wt and Dmdmdx in the
absence or presence of
autophagy and P2RX7 inhibi-
tors (3-MA [5 mM] and
A804598 [100 nM], respec-
tively). (D) Representative
western blots showing P2RX7
and LC3-II levels in Wt,
Dmdmdx and Dmdmdx p2rx7¡/¡
double-mutant myotubes
incubated for 30 min with
1 mM BzATP. Graph depicts
fold change in LC3-II levels in
Dmdmdx and Dmdmdx p2rx7¡/¡
myotubes compared to Wt
myotubes following 30 min
exposure to 1 mM BzATP.
Means C/¡ SE, n D 5, P < 0
.05*, 0.001** and 0.0001***.
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signaling between the P2RX7 LP and autophagy (Fig. 9). P2RX7
has a long C terminus, distinguishing it from other receptors of
the P2X family and which is essential in pore formation.51 It
would be interesting to establish whether this P2RX7-HSP90 is a
direct interaction, in which case it is worthwhile identifying the
specific P2RX7 domain(s) involved. Alterations in this binding
region(s) may be responsible for differences in P2RX7 function
in specific cells and may also have a role in pathologies. Previous
studies show that P2RX7Y550F substitution is associated with an
increase in the level of tyrosine phosphorylation of HSP90 but
without affecting the amount of HSP90 protein interacting with
the receptor.50 This might indicate that P2RX7 interaction with
heat shock proteins is indirect and it has been suggested that it
may involve ACTB/Actin, b, which is present in the P2RX7 sig-
naling complex.42 However, ACTB disruption by cytochalasin D
or latrunculin A does not alter LP functions.52 Moreover, our
finding that only HSP90 but not HSPA2 antagonist blocked
P2RX7 pore formation, while both blocked autophagic flux trig-
gered by P2RX7 activation points to functional specialization of
these two HSP proteins in the P2RX7 signaling complex.
Clearly, further studies should identify the exact interactions
between proteins of this complex. These are likely to vary in dif-
ferent cells and this has important implications for understanding
the function of P2RX7 and also for designing targeted pharmaco-
logical treatments.
BECN1 is a component of multiple PtdIns3K complexes that
are involved in autophagy and vacuolar protein sorting path-
ways53 and interacts functionally with HSP90.24 Therefore, we
have investigated the effect of HSP inhibition on BECN1 expres-
sion. Contrary to findings in macrophages, where inhibition of
HSP90 with GA reduced LC3-II responses through proteasomal
degradation of BECN1,24 there was a dose-dependent increase in
BECN1 levels in response to HSP90 or HSPA2 antagonists in
dystrophic myoblasts. The failure of chaperone and/or protea-
some machineries can trigger aggresome formation.54 Indeed, we
found that the increase in BECN1 following HSP inhibition in
dystrophic myoblasts was due to its accumulation in aggresomes.
Skeletal muscles, being a postmitotic tissue, are vulnerable to
misfolded and dysfunctional proteins55 and both human and
mouse dystrophic muscles have been shown to increasingly accu-
mulate proteins damaged through reactive oxygen species.56 In
dystrophic muscle cells, aggregation of BECN1 in the absence of
chaperone proteins coincided with an increase in reactive oxygen
species production (Fig. S1), resembling defective CFTR-driven
aggresome sequestration of BECN1 in cystic fibrosis.57
Autophagy is a highly controlled process: Regulatory coordi-
nation between heat shock proteins and autophagy has recently
been uncovered.58 Interestingly, the outcomes varied significantly
depending on the mode of activation; increased HSPA2 levels
prevented starvation-induced autophagy, while heat stress expo-
sure-induced HSPA2 increases were associated with increases in
autophagy.58 It is intriguing to consider that this complex inter-
action between 2 systems of cellular homeostasis may also involve
P2RX7 activation. Indeed, P2RX7 was recently found to be a key
modulator of metabolic oxidative stress-mediated autophagy in
experimental nonalcoholic steatohepatitis and this process also
involved HSPA2.59 Thus, a very similar mechanism is active in 2
different models of human diseases affecting liver and skeletal
muscles.
There is also crosstalk between autophagy and apoptosis,
which although not well understood, clearly facilitates a con-
trolled stress response.60 In many cases autophagy precedes apo-
ptosis and several proteins (e.g. BECN1) play important roles in
both pathways. Given that P2RX7 activation is known to trigger
apoptosis in many cell types and apoptosis in myoblasts has been
documented and reported to be a mediator of cell death in dys-
trophic muscles,61 we have examined whether these processes can
coexist in myoblasts. However, we found that although myoblasts
possess the capacity for responding to apoptotic stimuli, eATP
acting on P2RX7 receptors triggered CASP3-CASP7-indepen-
dent cell death in myoblasts.
The results reported here indicate that P2RX7 LP-mediated
autophagy may be the determining factor in the eATP-evoked
cell death cascade in dystrophic myoblasts. Although specific
parameters of autophagic cell death remain the topic of a
debate,62,63 our findings that (i) myoblast cell death occurs with-
out CASP activation, (ii) induction of autophagic flux is
Figure 9. Schematic depicting known interactions at the C terminus of
P2RX7 involving ACTB, ACTN (actinin, a), MYH9 (myosin, heavy polypep-
tide 9, non-muscle), and heat shock proteins mediating autophagic cell
death in dystrophic myoblasts following P2RX7 activation. HSPA2,
HSPA8, and HSP90 have been shown to bind P2RX7 C-terminal tail,
where Y550 residue plays an important role in mediating phosphoryla-
tion status of HSP90.42,50 In myoblasts, P2RX7 activation following ATP
released from damaged or degenerating muscles result in activation of
HSP90-mediated LP formation and autophagic flux, culminating in
CASP3-CASP7 independent cell death. Inhibition of HSP90 or of autoph-
agy prevented LP formation in myoblasts, indicating involvement of
HSP90-mediated autophagy in this process. Inhibition of HSPA2 resulted
in inhibition of autophagy but not LP formation or cell death.
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observed, and (iii) cell death is suppressed using inhibitors of
autophagy did fit fully with the autophagic cell death conditions
stipulated by Shen et al.64
Under physiological conditions, autophagy is responsible for
recycling of cytoplasmic contents. Under stress, cells use autoph-
agy as an element of homeostatic mechanisms maintaining suffi-
cient macromolecular and energy provisions. Our understanding
of the molecular mechanisms of the “basal autophagy” in skeletal
muscles has only just started to develop,22 but autophagy main-
taining cell homeostasis appears integral to muscle physiological
growth. Its activation could also be essential to the processes of
muscle repair. Therefore, the following scenario could be envis-
aged: Activation of P2RX7 by brief exposure to ATP and/or by
low-level danger signals (eATP) released in mild tissue damage
would be fully modulated by ecto-ATPases and thus could result
in a self-limiting stimulation of autophagy leading to recircula-
tion of damaged organelles and would aid muscle growth and
regeneration through beneficial, low level, tonic P2RX7 stimula-
tion. In contrast, as a ‘danger receptor’ P2RX7 becomes upregu-
lated only on muscle cells which are in danger, and in a chronic
damage state (e.g., in dystrophinopathy and dysferlinopathy)
large amounts of ATP and P2RX7 upregulation could lead to
prolonged, chronic stimulation and overactivation of authopha-
gic pathways, inducing autophagic muscle death. Furthermore,
SGCA, a specialized ecto-ATPase activated by high eATP levels,4
is lost from the sarcolemma of dystrophic muscles. This could
contribute to the creation of a vicious circle of pathology through
further overactivation of P2RX7 (for a review see ref.65).
However, the involvement of autophagy in DMD pathology
is unclear. Some studies indicate a positive role: De Palma et al.
report significantly lower levels of LC3-II in total muscle protein
extracts from both Dmdmdx leg and diaphragm muscles compared
with Wt animals and beneficial effects from autophagy augmen-
tation by limited food intake.66 However, a more recent study
reports that autophagy is impaired in Dmdmdx mouse leg but not
in diaphragm muscles.67 Pauly et al. report that autophagy stim-
ulation via AMPK agonist administration ameliorates dystrophic
features in Dmdmdx diaphragms.48 Rapamycin (an autophagy
activator via MTOR blockade) also significantly improves the
dystrophic phenotype.68 In contrast, in another study, phosphoi-
nositide 3-kinase-AKT (thymoma viral proto-oncogene)-MTOR
activation rather than blockade ameliorates pathology in Dmdmdx
utrn¡/¡ mouse.69 We also have examined LC3-II in tibialis ante-
rior and diaphragms of control and dystrophic Dmdmdx mice at
the same age and with the antibody used by De Palma et al.
There was a vast intragroup variability between muscle samples
but we found no significant difference in LC3-II levels between
normal and dystrophic muscles (Fig. S4). It is worth noting that
simple comparison of total LC3-II levels can be inaccurate as a
measure of autophagic status and measurements of autophagic
flux would provide a more informative assessment.31,32,37,38 The
importance of elucidating the true nature of the autophagic status
is highlighted by autophagic vacuolar myopathies, where levels of
autophagic markers are constitutively high through lack of proper
autophagosome and lysosome clearance and yet autophagy is
deemed defective and its restoration brings therapeutic benefits.70
Therefore, autophagy appears both down- and upregulated in
different muscle disorders with its upregulation proving benefi-
cial in mouse models of Collagen VI71 and Duchenne66 muscular
dystrophy while its inhibition gives positive outcomes in
LAMA2/laminin a2-deficient26,and DMD- and UTRN-defi-
cient mouse muscle.69 Separation of muscle from nonmuscle
effects might explain some of the discrepancies. Indeed, all stud-
ies to date that looked at autophagy in isolated muscle cells have
documented negative effects of increased autophagy levels (sum-
marized in Fig. S5). This fits with our finding that overactivation
of P2RX7 leading to increased autophagic flux resulted in cell
death of both myoblasts and myotubes.
However, in macrophages72,73 and dendritic cells74 increased
autophagy decreases inflammatory mediator release and increased
inflammatory mediator releases coincide with reduced autophagy
(Fig. S5).75 Thus, autophagy may have contrasting functions in
muscle and immune cells. It is important to consider this possi-
bility as dystrophic muscles are a hub of cellular interactions,
chiefly involving mature and proliferating muscle cells and infil-
trating immune cells. Therefore, when manipulating autophagy
levels any perceived benefit derived from a global inhibition of
autophagy should take into account effects that may relate to a
disease model, all cell types involved and in vitro or in vivo
scenarios.
Tonic versus excitotoxic activation profiles may govern the
roles of both autophagy and P2RX7 activation in muscle disease,
where ‘a little’ is good and even essential but ‘too much’ is inevi-
tably bad. Tonic stimulation of P2RX7 promotes myoblast pro-
liferation and differentiation,14,15 whereas high-level, stimulation
promotes excitotoxic cell death.5,14
It appears that high eATP acting through P2RX7 overex-
pressed on dystrophic muscle cells could activate a number of
mechanisms, including LP opening and efflux of the intracellular
content, signaling cascades, induction of cell death via autoph-
agy, and inhibition of regeneration. Therefore, blockade of this
receptor should have a more significant effect than treatments
addressing each of these pathways separately. In addition, the
antiinflammatory effects of blocking the P2RX7-NLRP3 inflam-
masome formation on infiltrating cells could ameliorate the dis-
ease symptoms further still.
As such, P2RX7 targeting may represent a more viable avenue
for therapy. The outcome of some preclinical trials with broad
P2 purinoceptor antagonists76 and our own studies with CBB5
and in Dmdmdx p2rx7¡/¡ double-mutant mice (manuscript sub-
mitted) may suggest that more specific, ‘drug-like’ P2RX7 antag-
onists may bring therapeutic gains in dystrophic muscles by
reducing inflammation and increasing muscle cell survival even
under conditions where eATP levels remain high. Moreover, a
recent study has highlighted the potential therapeutic benefits of
specifically inhibiting P2RX7 LP formation in the treatment of
chronic pain.77 Therapies combining selective anti-inflammatory
drugs78 with P2RX7 antagonists could result in improved effi-
cacy and reduced side effects compared to current DMD man-
agement with glucocorticoids.
In summary, our results in dystrophic myoblasts and myo-
tubes demonstrate a novel mechanism of autophagic cell death,
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which is triggered specifically by P2RX7 LP formation and
requires interactions with heat shock proteins. Moreover, we
reveal reciprocity in this mechanism in muscles but not in macro-
phages, whereby P2RX7 LP formation requires autophagy and is
HSP90-dependent but HSPA2-independent. Finally, we show
that molecules entering through the LP can be targeted to auto-
phagosomes. Targeting this P2RX7-autophagy axis could be of
therapeutic benefit in this debilitating and life-shortening form
of muscular dystrophy.
Materials and Methods
Animals
C57BL10ScSn, Dmdmdx and Dmdmdx p2rx7¡/¡ double-
mutant 4-mo-old male mice were used in accordance with appro-
vals granted by the institutional Ethical Review Board and the
Home Office (UK). To generate Dmdmdx p2rx7¡/¡ double-
mutant animals (manuscript submitted) a female Dmdmdx mouse
was crossed with a male p2rx7 knockout mouse (Jackson lab s/n:
005576).79 Following selective breeding, animals were genotyped
by PCR using specific primer sets to the Dmdmdx mutation80 and
the neomycin cassette79 and a colony of homozygous double-
mutant Dmdmdx p2rx7¡/¡ double-mutant animals was estab-
lished. All mice were bred and maintained in a controlled envi-
ronment (12 h light-dark cycle, 19–23C ambient temperature,
45–65% humidity). They were fed a standard pellet diet (Econ-
omy Rodent Breeder Diet, Special Diet Services, Witham, UK)
and allowed water ad libitum. Mice were killed by CO2 inhala-
tion and organs dissected and flash frozen in liquid nitrogen prior
to protein extraction.
Cell cultures
Wild-type and dystrophic myoblast cell lines derived from
adult male “immorto” mice were as previously described.5,81
Myoblasts and myotubes were cultured as primary cells without
immortalization stimulus. Culture media consisted of KnockOut
DMEM (Invitrogen, 10829–018) supplemented with 20% v/v
KnockOut serum replacement (KSR; Invitrogen, 10828–028),
10% v/v donor horse serum (Sera Labs, S-222-FSI) and 2 mM
L-glutamine (Sigma, G7513). Myoblast to myotube differentia-
tion was induced by withdrawing KSR and reducing donor horse
serum to 5% v/v. Peritoneal macrophages were isolated by perito-
neal cavity lavage with 5ml ice cold Dulbecco’s phosphate-buff-
ered saline (DPBS; Sigma, D8537) containing 2% KSR and
were maintained under the same conditions as myoblast cultures.
J774 (J774A.1 cell line) mouse macrophages were purchased
from American Type Culture Collection (TIB-67) and cultured
as per myoblasts. Primary myoblasts were obtained from freshly
dissected muscles from 4 month-old male mice as previously
described.5 HEK-293 cells stably transfected with mouse P2RX7
cDNA (courtesy of Dr. Friedrich Koch-Nolte, Hamburg) and
HEK-293 control cells were cultured in media containing 10%
v/v Fetal Bovine Serum (Sigma, F9665) and 2 mM L-glutamine
(Sigma, G7513).
Antibodies and reagents
The following antibodies were used: anti-P2RX7 (Synaptic
Systems, 177003) 1:1000, anti-MAPK1-MAPK3 (Cell Signaling
Technology, 9102) 1:2000, anti-phospho-MAPK1-MAPK3
(Cell Signaling Technology, 9106) 1:1000, anti-ACTB (Sigma,
A2066) 1:1000, anti-LC3B (Sigma, L7543) 1:1000, anti-
GAPDH (Sigma, G9545) 1:1000, anti-COX4/COXIV (Abcam,
ab14744) 1:000, anti-BECN1 (Santa Cruz Biotechnology,
48381) 1:200. Other chemicals used were as follows: P2RX7
antagonists A438079 and A804598 (Tocris Bioscience, 2972
and 4473, respectively) and Brilliant Blue G (BBG, Ascent Scien-
tific, ASC-389), HSPA2 and HSP90 inhibitors, VER155008,
geldanamycin and 17-DMAG (Tocris Biosciences, 3803, 1368
and 2610, respectively), Proteostat aggresome detection kit
(Enzo Life Sciences, ENZ-51035-K100), HSPA2 inhibitor
KNK437 (Merck Millipore, 373260), the cell permeable, fluoro-
genic CASP3-CASP7 substrate DEVD-Nucview488 (Cambridge
Biosciences, BT10403) and the mitochondrial membrane poten-
tial-sensitive probe tetramethylrhodamine ethyl ester (TMRE;
Sigma, 87917), digoxin and digitoxigenin (Sigma, D6770 and
D9404, respectively).
Western blotting
Proteins were extracted from adherent cells by scraping in
100 ml ice-cold extraction buffer containing 1 x LysisM (Roche,
04719956001), 1x cOmplete ULTRA Mini EDTA-free protease
inhibitor cocktail tablet (Roche, 05892791001), 1 x PhosSTOP
phosphatase inhibitor cocktail tablet (Roche, 04906845001),
2 mM sodium orthovanadate (Sigma, S6508). Cells were dis-
rupted by passing 10 times through a 25 g needle followed by
centrifugation for 30 s at 800 g. Total proteins from frozen tis-
sues were extracted in ice-cold extraction buffer (as above) using
50 passes between glass Teflon homogenizers (Fisher Scientific,
11592453). Samples were centrifuged (800 g for 3 min at 4C)
to remove debris and concentrations determined using the Bicin-
choninic acid assay kit (Sigma, B9643). Twenty to 40 mg protein
was mixed with Laemmli buffer at 1:1 v/v ratio with 2.5% v/v
b-mercaptoethanol, heated for 5 min at 95C, then chilled on
ice prior to gel loading. Samples were separated on Any-KD
Mini-protean TGX ready gels (Bio-Rad, 456–9034) and electro-
blotted onto Hybond-P membranes (GE Healthcare,
RPN303F). Blots were blocked in 5% w/v nonfat milk powder
in 1x Tris buffered saline (TBST; 50 Mm Tris, 150 mM NaCl,
0.01% v/v Tween-20, Sigma T1503, S7653 and P1379, respec-
tively), for 1 h prior to probing with primary antibody diluted in
the same blocking buffer (overnight at 4C or 2 h at room tem-
perature), then washed (3 times) with 1 x TBST for 10 min and
incubated with the appropriate horseradish peroxidase-conju-
gated secondary antibody; anti-mouse 1:10:000 (Sigma, A4416),
anti-rabbit 1:5000 (Sigma, A6154) overnight at 4C or 1 h at
room temperature. Specific protein bands were visualized using
Luminata Classico or Forte chemiluminescent substrates (Merck
Millipore, WBLUC0500 and WBLUF0500, respectively),
images were obtained using a ChemiDoc MP system (Bio-Rad,
Hertfordshire, UK). Alexa Fluor 488 anti-mouse and 555 anti-
rabbit secondary antibodies (Life Technologies, A-11034 and
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A-21429, respectively) were used for fluorescence detection of
MAPK1-MAPK3 activation and images obtained using a LI-
COR Odyssey Fc imaging system (Cambridge, Cambridgeshire,
UK). Densitometric analyses were performed using the inte-
grated density measurement function of ImageJ software.82 All
experiments were repeated at least 3 times in triplicate with simi-
lar results obtained throughout.
LC3-II induction assay
Cells were seeded at numbers providing 70% confluency
in 6-well plates (Nunc, 10119831) in 2 ml of medium. After
24 h, growth medium was replaced with one containing 10%
V/V KSR. Cells were incubated for a further 16 h prior to
application of agonists and antagonists. ATP (3 mM) and the
semispecific P2RX7 agonist BzATP (1 mM; Sigma, B6396)
were applied for 30 min, with or without 30 min preincuba-
tion with P2RX7 antagonists A804598 (100 nM; Tocris,
4473) or Brilliant Blue G (BBG, 10 mM; Ascent Scientific,
ASC-389). Where indicated, cells were preincubated for
30 min with autophagy inhibitors: 3-methyladenine (3-MA,
5 mM; Sigma, M9281), mefloquine hydrochloride (Mefloq.,
1 mM, Bioblocks, QUO24–1), the lysomal protease inhibi-
tors: Pepstatin A and E-64d (both at 10 mg/ml; Sigma 77170
and E8640, respectively), or the cardiac glycoside autosis
inhibitors digoxin and digitoxigenin (5 mM; Sigma, D6770
and D9404, respectively). Cells were washed in 1 x PBS,
then scraped in 100 ml ice-cold lysis buffer (as above) and
lysed by 10 passes through a 25 g needle. Samples were cen-
trifuged at 800 g for 30 s to remove insoluble materials.
Phosphoprotein mass spectrometry analysis
Cells were seeded at 70% confluency in 600-cm2 plates
(Nunc, 166508) in 135 ml of medium for 24 h prior to the
addition of 3 mM ATP for 10 min. Cells were washed in 1 x
DPBS (Sigma, D8537), then scraped into 3 ml ice cold lysis
buffer (as above) and homogenized by 10 passes through a 25 g
needle. Samples were centrifuged at 800 g for 30 s to remove
insoluble materials, prior to phosphoprotein purification per the
manufacturer’s instructions (Phosphoprotein Purification Kit,
Pierce, 88512). Samples were then desalted using maxi dialysis
tubes (3 ml, 3.5 kDa; Generon, DO35) floating in cold, double-
distilled H2O for 2 h, then for a further 16 h in fresh dialysis
solution. Sample pH was adjusted to pH 6.0 using triethylam-
monium (Sigma, 90357), then samples were denatured in 5 mM
tris(2-carboxyethyl)phosphine hydrochloride (TCEP; Sigma
C4706) in triethylammonium (Sigma, 90357) at 60C for 1 h.
Cysteine residues were blocked in 55 mM iodoacetamide Sigma,
I1149) at RT for 30 min. Samples were trypsin digested in 1 mg
trypsin (Promega, V5111) per 1 mg protein at 30C for 15 min.
Samples were then iTraq labeled from 114–117 (Sciex,
4374321) dissolved in EtOH for 1 h at RT, then subjected to
isoelectric focusing in 24 well, 12.5% w/v polyacrylamide gel
strips (Agilent Technologies, 5188–6424) using an OFFGEL
fractionating system (Agilent 3100 Fractionator, Agilent Tech-
nologies, Massy, Paris, France) for 48 h. Separated samples were
analyzed by ESI-LC-MS (Agilent 6200 TOF, Agilent
Technologies, Massy, Paris, France) and phosphopeptide frag-
ments identified by interrogating the Mascot database (Matrix
Science) using Spectrum Mill software (Agilent Technologies).
Fold changes and significance levels were determined using the
iQuantitator40 algorithm and pathway analysis carried using
pathway designer functions of Metacore (Thomson Reuters) and
IPA (Ingenuity, Qiagen) software.
Large pore, CASP3-CASP7, and cell viability assays
Myoblasts and peritoneal macrophages were plated onto
3 cm dishes or 96-well plates (Nunc, 11810765 and
10212811, respectively) and cultured for 24 h in normal
growth medium, followed by 16 h in low-serum medium
(10% v/v KSR). For dye uptake assays, cells were incubated
in the Large Pore (LP) buffer (145 mM NaCl, 5 mM KCl,
1 mM MgCl2, 10 mM Na-HEPES) containing 5 mM ethi-
dium bromide (EtBr; Sigma E1510) or 3 mM Lucifer Yellow
(LY; Sigma, L0259) dyes for LP assays or 5 mM Nucview488
(Cambridge Biosciences, BT10403) and 200 nM TMRE
(Sigma, 87917) for CASP3-CASP7 assays. Following addition
of agonists, dye uptake was analyzed using LSM 510 Meta
microscope (Zeiss, Cambridge, Cambridgeshire, UK) with
heated stage and 40 x immersion lens and using a POLAR-
star Optima plate reader (BMG Labtech, Aylesbury, Bucking-
hamshire, UK) for 96-well plates. Time-lapse images and
fluorescence measurements were taken at 15 min intervals
from 0 to 60 min. At the end of each time course, 50 mg/ml
digitonin (Sigma, D141) was added to nonselectively permea-
bilize all cells. Cell viability was assessed using LDH release
(Sigma, TOX7) and PrestoBlue (Life Technologies, A-13261)
assay kits as per the manufacturers’ instructions.
For immunolocalization of LC3 with dyes in LP assays,
dystrophic myoblasts were grown on coverslips, incubated in
the LP buffer containing 3 mM LY and treated with 1 mM
BzATP for 25 min, after which cells were washed 3 times in
1 x PBS, then fixed in ice-cold 4% paraformaldehyde for
30 min. N.B. LY can be covalently linked to surrounding
biomolecules by aldehyde, allowing dye localization in cellu-
lar compartments of fixed cells. Following 3 further washes
in PBS, cells were permeabilized in 0.1% Triton X-100 in
PBS, blocked with serum specific to the host of the secondary
antibody origin (10%; Sera Labs, S-707-HIS) for 30 min at
RT, then incubated with anti-LC3 antibody (Sigma, L7543)
overnight at 4C. Cells were then washed 3 times in 1 x PBS
prior to secondary antibody (Alexa Fluor) application for 1 h
at room temperature. Coverslips were then washed and
mounted on slides using mounting medium (Ibidi, 5000),
and images acquired using a Zeiss LSM 5.10 confocal micro-
scope (Zeiss, Cambridge, Cambridgeshire, UK). Images were
analyzed using ImageJ software’s particle analysis plugin.
Aggresome assays
Myoblasts were cultured on coverslips as per the LP assay.
Cells were pretreated with 75 nM GA prior to 1 mM BzATP
treatment for 25 min, washed 3 times in 1 x PBS and fixed
in ice-cold 4% paraformaldehyde for 30 min. Following 3
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further washes in PBS, cells were permeabilized in 0.1% Tri-
ton X-100 in PBS, blocked with goat serum (10%; Sera
Labs, S-707-HIS) in PBS for 30 min at room temperature,
then incubated with primary BECN1 antibody overnight at
4C. Cells were then washed 3 times in 1 x PBS prior to sec-
ondary antibody (Alexa Fluor 488 anti-mouse; Life Technolo-
gies, A-11029) application for 1 h at room temperature.
Aggresomes were detected using the Proteostat aggresome
detection kit (Enzo Life Sciences, ENZ-51035-K100) accord-
ing to the manufacturer’s instructions. Coverslips were
mounted on slides using FluorPreserve mounting media and
images acquired using a Zeiss LSM 5.10 confocal microscope.
Images were analyzed using ImageJ software’s particle analysis
and colocalization plugins.
Statistical analysis
Results are reported as means C/¡ SEM where n refers to
number of independent experiments (3 to 5). For statistical anal-
ysis, a one-way analysis of variance (ANOVA) was performed
using the post-hoc Tukey test (Microcal Origin 7.0). Differences
were considered statistically significant at P <0 .05.
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